---
document_datetime: 2026-02-06 10:45:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xerava.html
document_name: xerava.html
version: success
processing_time: 0.1180635
conversion_datetime: 2026-02-09 22:35:00.92313
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Academia](/en/partners-networks/academia)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One substance - one assessment](/en/partners-networks/one-substance-one-assessment-osoa-eu-collaboration-chemicals-related-data)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Xerava

# Xerava

[RSS](/en/individual-human-medicine.xml/66660)

##### Authorised

This medicine is authorised for use in the European Union

eravacycline Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xerava](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-83313)
- [More information on Xerava](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xerava is an antibiotic used to treat complicated intra-abdominal (belly) infections (cIAI) in adolescents from 12 years of age who weigh at least 50 kg and in adults. 'Complicated' means that the infection is difficult to treat because it has spread to the abdominal space.

Xerava contains the active substance eravacycline.

Expand section

Collapse section

## How is Xerava used?

Xerava can only be obtained with a prescription and prescribers should take into account official guidance on the use of antibiotics.

Xerava is given by infusion (drip) into a vein over one hour. It is given once every 12 hours for at least 4 days and up to 14 days. The dose depends on the patient's weight, and may be increased if the patient is also taking a type of medicine called a 'strong CYP3A4 inducer'.

For more information about using Xerava, see the package leaflet or contact your doctor or pharmacist.

## How does Xerava work?

The active substance in Xerava, eravacycline, belongs to a group of antibiotics called tetracyclines. Tetracyclines work by attaching to and blocking part of the cell machinery in bacteria that is involved in making proteins. This leads to the death of the bacteria causing the infection.

## What benefits of Xerava have been shown in studies?

Xerava was shown to be as effective as alternative antibiotics in 2 main studies involving adults with cIAIs. The main measure of effectiveness in both studies was whether the infection was cured.

In the first study involving 538 adults, Xerava was compared with ertapenem (another antibiotic). After around a month, 87% of people treated with Xerava were cured of their infection, compared with 89% of those treated with ertapenem.

In the second study involving 499 adults, Xerava was compared with meropenem (another antibiotic). After around a month, 92% of people treated with Xerava and 92% of those treated with meropenem were cured of their infection.

The company also provided data on how the medicine behaves in the body in children aged 8 to 17 years with a suspected or confirmed bacterial infection. These data were inconclusive and it was therefore not possible to establish an appropriate dose for children below 12 years of age or for adolescents from 12 years of age weighing less than 50 kg.

## What are the risks associated with Xerava?

For the full list of side effects and restrictions with Xerava, see the package leaflet.

The most common side effects with Xerava in adults (seen in up to 1 in 10 people in clinical trials) include nausea (feeling sick), vomiting, phlebitis (inflammation of a vein) at the site of infusion, phlebitis, thrombosis (formation of blood clots in the blood vessels) at the infusion site, diarrhoea, reactions at the site of the infusion including reddening of skin and reduced sense of touch and pain, thrombophlebitis (inflammation of veins caused by a blood clot), hyperhidrosis (excessive sweating) and headache.

The most common side effects with Xerava in children (seen in more than 1 in 10 people in a clinical trial) include nausea, vomiting, headache and hyperhidrosis.

Xerava must not be used in patients who are hypersensitive to other tetracycline antibiotics.

## Why is Xerava authorised in the EU?

Xerava is as effective as alternative antibiotics in treating infections caused by various types of bacteria and achieves high cure rates. Since Xerava is expected to behave in a similar way in adolescents from 12 years of age and weighing at least 50 kg as in adults, its use can be extended to this population. Xerava's safety profile is considered acceptable. The European Medicines Agency therefore decided that Xerava's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Xerava?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xerava have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xerava are continuously monitored. Side effects reported with Xerava are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xerava

Xerava received a marketing authorisation valid throughout the EU on 20 September 2018.

Xerava : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-35819

English (EN) (108.38 KB - PDF)

**First published:** 08/10/2018

**Last updated:** 06/02/2026

[View](/en/documents/overview/xerava-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-621)

български (BG) (133.65 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/bg/documents/overview/xerava-epar-medicine-overview_bg.pdf)

español (ES) (109.48 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/es/documents/overview/xerava-epar-medicine-overview_es.pdf)

čeština (CS) (131.86 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/cs/documents/overview/xerava-epar-medicine-overview_cs.pdf)

dansk (DA) (108.44 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/da/documents/overview/xerava-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.65 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/de/documents/overview/xerava-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.06 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/et/documents/overview/xerava-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.2 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/el/documents/overview/xerava-epar-medicine-overview_el.pdf)

français (FR) (111.01 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/fr/documents/overview/xerava-epar-medicine-overview_fr.pdf)

hrvatski (HR) (134.11 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/hr/documents/overview/xerava-epar-medicine-overview_hr.pdf)

italiano (IT) (108.92 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/it/documents/overview/xerava-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (129 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/lv/documents/overview/xerava-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (131.74 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/lt/documents/overview/xerava-epar-medicine-overview_lt.pdf)

magyar (HU) (131.64 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/hu/documents/overview/xerava-epar-medicine-overview_hu.pdf)

Malti (MT) (133.13 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/mt/documents/overview/xerava-epar-medicine-overview_mt.pdf)

Nederlands (NL) (109.46 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/nl/documents/overview/xerava-epar-medicine-overview_nl.pdf)

polski (PL) (135.9 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/pl/documents/overview/xerava-epar-medicine-overview_pl.pdf)

português (PT) (110.56 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/pt/documents/overview/xerava-epar-medicine-overview_pt.pdf)

română (RO) (128.16 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/ro/documents/overview/xerava-epar-medicine-overview_ro.pdf)

slovenčina (SK) (132.12 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/sk/documents/overview/xerava-epar-medicine-overview_sk.pdf)

slovenščina (SL) (129.92 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/sl/documents/overview/xerava-epar-medicine-overview_sl.pdf)

Suomi (FI) (107.14 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/fi/documents/overview/xerava-epar-medicine-overview_fi.pdf)

svenska (SV) (107.95 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/sv/documents/overview/xerava-epar-medicine-overview_sv.pdf)

Xerava : EPAR - Risk-management-plan summary

English (EN) (198.19 KB - PDF)

**First published:** 08/10/2018

**Last updated:** 20/04/2023

[View](/en/documents/rmp-summary/xerava-epar-risk-management-plan-summary_en.pdf)

## Product information

Xerava : EPAR - Product Information

English (EN) (542.39 KB - PDF)

**First published:** 08/10/2018

**Last updated:** 06/02/2026

[View](/en/documents/product-information/xerava-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-146)

български (BG) (889.42 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/bg/documents/product-information/xerava-epar-product-information_bg.pdf)

español (ES) (860.6 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/es/documents/product-information/xerava-epar-product-information_es.pdf)

čeština (CS) (926.69 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/cs/documents/product-information/xerava-epar-product-information_cs.pdf)

dansk (DA) (832.98 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/da/documents/product-information/xerava-epar-product-information_da.pdf)

Deutsch (DE) (757.23 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/de/documents/product-information/xerava-epar-product-information_de.pdf)

eesti keel (ET) (805.35 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/et/documents/product-information/xerava-epar-product-information_et.pdf)

ελληνικά (EL) (898.28 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/el/documents/product-information/xerava-epar-product-information_el.pdf)

français (FR) (894.12 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/fr/documents/product-information/xerava-epar-product-information_fr.pdf)

hrvatski (HR) (850.96 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/hr/documents/product-information/xerava-epar-product-information_hr.pdf)

íslenska (IS) (790.2 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/is/documents/product-information/xerava-epar-product-information_is.pdf)

italiano (IT) (823.16 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/it/documents/product-information/xerava-epar-product-information_it.pdf)

latviešu valoda (LV) (874.03 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/lv/documents/product-information/xerava-epar-product-information_lv.pdf)

lietuvių kalba (LT) (870.43 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/lt/documents/product-information/xerava-epar-product-information_lt.pdf)

magyar (HU) (890.51 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/hu/documents/product-information/xerava-epar-product-information_hu.pdf)

Malti (MT) (959.43 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/mt/documents/product-information/xerava-epar-product-information_mt.pdf)

Nederlands (NL) (850.74 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/nl/documents/product-information/xerava-epar-product-information_nl.pdf)

norsk (NO) (781.29 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/no/documents/product-information/xerava-epar-product-information_no.pdf)

polski (PL) (884.81 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/pl/documents/product-information/xerava-epar-product-information_pl.pdf)

português (PT) (859.22 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/pt/documents/product-information/xerava-epar-product-information_pt.pdf)

română (RO) (873.91 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/ro/documents/product-information/xerava-epar-product-information_ro.pdf)

slovenčina (SK) (915.18 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/sk/documents/product-information/xerava-epar-product-information_sk.pdf)

slovenščina (SL) (877 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/sl/documents/product-information/xerava-epar-product-information_sl.pdf)

Suomi (FI) (842.42 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/fi/documents/product-information/xerava-epar-product-information_fi.pdf)

svenska (SV) (493.41 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/02/2026

[View](/sv/documents/product-information/xerava-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000265697 18/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xerava : EPAR - All Authorised presentations

English (EN) (57.58 KB - PDF)

**First published:** 08/10/2018

**Last updated:** 20/07/2021

[View](/en/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-265)

български (BG) (67.81 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/bg/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_bg.pdf)

español (ES) (57.81 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/es/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.6 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/cs/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (59.75 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/da/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.42 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/de/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (57.63 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/et/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.37 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/el/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_el.pdf)

français (FR) (58.53 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/fr/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (114.49 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/hr/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (60.01 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/is/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_is.pdf)

italiano (IT) (57.38 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/it/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.5 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/lv/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (75.32 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/lt/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (77.14 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/hu/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (76.84 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/mt/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (58.04 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/nl/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (59.84 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/no/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_no.pdf)

polski (PL) (75.5 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/pl/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.53 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/pt/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.9 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/ro/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (74.37 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/sk/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (66.45 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/sl/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.04 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/fi/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (58.67 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/sv/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xerava Active substance eravacycline International non-proprietary name (INN) or common name eravacycline Therapeutic area (MeSH)

- Infection
- Bacterial Infections

Anatomical therapeutic chemical (ATC) code J01AA13

### Pharmacotherapeutic group

Tetracyclines

### Therapeutic indication

Xerava is indicated in adolescents from the age of 12 years weighing at least 50 kg, and in adults, for the treatment of complicated intra-abdominal infections (cIAI).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/004237 Marketing authorisation holder

PAION Pharma GmbH

Heussstraße 25 Brand 52078 Aachen Germany

Marketing authorisation issued 20/09/2018 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xerava : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (155.53 KB - PDF)

**First published:** 06/02/2026

[View](/en/documents/procedural-steps-after/xerava-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xerava : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (180.62 KB - PDF)

**First published:** 10/07/2019

**Last updated:** 06/02/2026

[View](/en/documents/procedural-steps-after/xerava-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Xerava : EPAR - Public assessment report

Reference Number: EMA/540193/2018

English (EN) (2.99 MB - PDF)

**First published:** 08/10/2018

[View](/en/documents/assessment-report/xerava-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xerava

Adopted

Reference Number: EMA/CHMP/447907/2018

English (EN) (68.46 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xerava_en.pdf)

#### News on Xerava

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Xerava : EPAR - Product information - tracked changes

English (EN) (180.87 KB - DOCX)

**First published:** 06/02/2026

[View](/en/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-137)

български (BG) (161.68 KB - DOCX)

**First published:**

06/02/2026

[View](/bg/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_bg.docx)

español (ES) (150.86 KB - DOCX)

**First published:**

06/02/2026

[View](/es/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_es.docx)

čeština (CS) (141.68 KB - DOCX)

**First published:**

06/02/2026

[View](/cs/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (149.74 KB - DOCX)

**First published:**

06/02/2026

[View](/da/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (148.45 KB - DOCX)

**First published:**

06/02/2026

[View](/de/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (144.24 KB - DOCX)

**First published:**

06/02/2026

[View](/et/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (170.66 KB - DOCX)

**First published:**

06/02/2026

[View](/el/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_el.docx)

français (FR) (134.78 KB - DOCX)

**First published:**

06/02/2026

[View](/fr/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (141.03 KB - DOCX)

**First published:**

06/02/2026

[View](/hr/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (140.9 KB - DOCX)

**First published:**

06/02/2026

[View](/is/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_is.docx)

italiano (IT) (153.77 KB - DOCX)

**First published:**

06/02/2026

[View](/it/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (159.41 KB - DOCX)

**First published:**

06/02/2026

[View](/lv/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (145.97 KB - DOCX)

**First published:**

06/02/2026

[View](/lt/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (158.9 KB - DOCX)

**First published:**

06/02/2026

[View](/hu/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (141.32 KB - DOCX)

**First published:**

06/02/2026

[View](/mt/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (153.15 KB - DOCX)

**First published:**

06/02/2026

[View](/nl/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (141.98 KB - DOCX)

**First published:**

06/02/2026

[View](/no/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_no.docx)

polski (PL) (155.38 KB - DOCX)

**First published:**

06/02/2026

[View](/pl/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_pl.docx)

português (PT) (146.23 KB - DOCX)

**First published:**

06/02/2026

[View](/pt/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_pt.docx)

română (RO) (148.04 KB - DOCX)

**First published:**

06/02/2026

[View](/ro/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (156.18 KB - DOCX)

**First published:**

06/02/2026

[View](/sk/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (152.03 KB - DOCX)

**First published:**

06/02/2026

[View](/sl/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (151.33 KB - DOCX)

**First published:**

06/02/2026

[View](/fi/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (149.8 KB - DOCX)

**First published:**

06/02/2026

[View](/sv/documents/product-information-tracked-changes/xerava-epar-product-information-tracked-changes_sv.docx)

#### More information on Xerava

- [EMEA-001555-PIP01-13-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001555-pip01-13-m05)
- [Xerava - opinion on variation to marketing authorisation](/en/medicines/human/variation/xerava)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/02/2026

## Share this page

[Back to top](#main-content)